Pyruvate dictates redox balance and cell size, establishing metabolism as a dominant regulator of cellular fitness, unveiling new strategies to modulate cancer, regeneration, and diabetes.

The firm will share updated data and new analyses from its Phase III trial with the agency, which issued a complete response ...

AGIO faces uncertainty as the FDA misses its Dec. 7 deadline related to the sNDA for Pyrukynd in thalassemia and offers no new timeline.

Agios Pharmaceuticals has seen its fair value estimate cut from roughly $42.33 to about $32.13 per share, as analysts recalibrate expectations following mixed clinical outcomes and a more uncertain ...

Topline results from the RISE UP phase 3 trial demonstrated that mitapivat significantly improved hemoglobin response in patients with sickle cell disease.